Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study
| Autor: | Marta Wawrzynowicz-Syczewska, A Horban, Łukasz Laurans, A. Staniaszek, Iwona Orłowska, Teresa Belica-Wdowik, Marek Sitko, Ewa Janczewska, Małgorzata Pawłowska, Barbara Baka-Ćwierz, Magdalena Tudrujek, Jerzy Jaroszewicz, Krzysztof Tomasiewicz, Anna Piekarska, Jolanta Białkowska, Agnieszka Czauż-Andrzejuk, Rafał Krygier, Dorota Dybowska, Włodzimierz Mazur, Andrzej Gietka, Beata Lorenc, Witold Dobracki, Olga Tronina, Łukasz Socha, Dorota Zarębska-Michaluk, Waldemar Halota, Hanna Berak, K. Simon, Jolanta Citko, Robert Flisiak, Aleksander Garlicki, Zbigniew Deroń |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Ledipasvir
Adult Liver Cirrhosis Male medicine.medical_specialty Sofosbuvir Genotype Hepacivirus Antiviral Agents 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Pegylated interferon Virology Internal medicine Surveys and Questionnaires medicine Humans 030212 general & internal medicine Adverse effect Aged Retrospective Studies Aged 80 and over Hepatology business.industry Ribavirin Hepatitis C Chronic Middle Aged Ombitasvir Regimen Infectious Diseases Treatment Outcome chemistry Paritaprevir 030211 gastroenterology & hepatology Female Poland business medicine.drug |
| Popis: | The aim of the EpiTer-2 study was to analyse patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis. The most common was genotype 1b (86.8%). The study population was gender balanced, the majority of patients were overweight or obese and 69% presented comorbidities, with the highest prevalence that for hypertension. More than half of patients were retreated due to failure of previous therapy with pegylated interferon and ribavirin. Almost two-third of patients received current therapy with ombitasvir/paritaprevir/ritonavir±dasabuvir (OPrD) ±ribavirin. Other patients received mostly sofosbuvir-based regimens including combination with ledipasvir and pegylated interferon and ribavirin for genotype 3-infected patients. Efficacy of treatment in the whole study population measured as intent-to-treat analysis was 95%. The most frequent regimen, administered for patients infected with genotype 1b, was 12 weeks of OPrD, resulting in an SVR rate of 98%. At least one adverse event was reported in 38% of patients, and the death rate was 0.8%. In conclusion, data from the EpiTer-2 study confirmed the excellent efficacy and safety profile of the real-world experience with recently introduced therapeutic options for genotype 1 HCV infection, but demonstrated weakness of the current therapeutic programme regarding genotype 3 infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|